Risk stratification for PML in patients treated with Tysabri
Risk stratification for PML in patients treated with Tysabri
Abstract
Natalizumab is a highly effective immunomodulator in the treatment of multiple sclerosis (MS).
Treatment with natalizumab has been associated with progressive multifocal leukoencephalopathy (PML), an infection of the central nervous system (CNS) caused by a pathogenic form of the normally benign JC virus (JCV).
We searched PubMed and used current data from the natalizumab global safety database to assess risk factors and quantify the risk of PML.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2315 Views
-
Last post by NHE
-
- 6 Replies
- 6740 Views
-
Last post by ElliotB
-
- 0 Replies
- 1370 Views
-
Last post by NHE
-
- 0 Replies
- 3438 Views
-
Last post by NHE
-
- 0 Replies
- 3164 Views
-
Last post by NHE
-
- 0 Replies
- 1450 Views
-
Last post by NHE
-
- 1 Replies
- 1524 Views
-
Last post by NHE
-
- 11 Replies
- 3397 Views
-
Last post by NHE
-
- 1 Replies
- 1028 Views
-
Last post by NHE